Prescribed Reading: No such thing as unicorns

Both closely watched Axovant and Intarcia had major setbacks this week, despite high hopes that their therapies would be game-changers. 

By Lisa LaMotta • Sept. 29, 2017

A drug 15 years in the making: Alnylam's quest to prove RNAi

This month's success from the APOLLO study puts the biotech on the brink of making the technology a medical reality for patients.

By Ned Pagliarulo • Sept. 29, 2017

Explore the Trendline➔

Radiopharmaceuticals

A series of technological advances have led to an explosion of scientific progress — and dealmaking — involving medicines that can precisely deliver radioactive materials into tumors.   

By BioPharma Dive staff

Zynerba shares up on rare disease trial success

Cannabis-based company's Phase 2 trial met its primary endpoint in Fragile X, shooting its shares up over 50%.

By Suzanne Elvidge • Sept. 29, 2017

Pharma tackles the ever-present problem of unmet need

Industry executives are focused on targeting what they see as the largest untapped markets. 

By Lisa LaMotta • Sept. 27, 2017

Mateon shuts down lead trial due to bad data

The small biotech will lay off 60% of its staff after halting its most advanced clinical study due to lack of efficacy. 

By Lisa LaMotta • Sept. 27, 2017

PureTech's Gelesis touts obesity drug's success in study

But a miss on one of the study's co-primary endpoints could complicate the company's pitch to the FDA.

By Suzanne Elvidge • Sept. 26, 2017

Arbutus' hepatitis B drug shows Phase 2 promise

Fresh data in hand, Arbutus plans to advance its lead RNAi therapeutic into a new study later this year. 

By Suzanne Elvidge • Sept. 26, 2017

Axovant's closely watched Alzheimer's drug fails late-stage trial

Intepirdine failed to meet either of the study's endpoints, sending shares in the unorthodox biotech down more than 70%.

By Ned Pagliarulo • Sept. 26, 2017

Acer jumps on 7-year-old data

The rare disease drugmaker's stock rose nearly 10% after announcing it had confirmed results from a 2010 study of celiprolol.

By Jacob Bell • Sept. 25, 2017

Allergan touts new data from failed NASH study

Cenicriviroc didn't meet the CENTAUR study's primary endpoint, but did show benefit in liver fibrosis.

By Jacob Bell • Sept. 22, 2017

Versartis crashes after Phase 3 miss

Friday's setback throws the biotech's plans to bring a long-acting human growth hormone to market into doubt.

By Ned Pagliarulo • Sept. 22, 2017

Prescribed Reading: Consolidation, clinical holds and landmark results

The FDA continues its clinical hold spree for PD-1/L1s, consolidation is rampant in the CDMO space and RNAi may become a reality very soon. 

By Lisa LaMotta • Sept. 22, 2017

Intercept shares plummet on FDA warning

A FDA safety alert for Ocaliva, following a 'Dear Dr.' letter last week, knocked 25% off Intercept's stock.

By Suzanne Elvidge • Sept. 22, 2017

Alzheimer's drug development just as challenging as ever

While biotech holds its breath for results from Axovant, a report from PhRMA showcases how hard it is to bring a new treatment to market.

By Lisa LaMotta • Sept. 21, 2017

Provention builds pipeline with Janssen licensing deal

Launched earlier this year, Provention now boasts a lineup of three in-licensed drug candidates.

By Ned Pagliarulo • Sept. 21, 2017

Alnylam soars on trial win for RNAi drug

Patisiran's success marks a major milestone for the Cambridge biotech, which has spent 15 years developing the science behind its RNA interference approach. 

By Ned Pagliarulo • Sept. 20, 2017

Supernus tweaks ADHD studies to boost chances of success

A planned interim analysis prompted the Maryland specialty pharma to drop a low dose of its drug for impulsive aggression in two Phase 3 trials. 

By Suzanne Elvidge • Sept. 19, 2017

AbbVie, Roche to seek broader market for leukemia drug after trial success

The drugmakers hope Venclexta could replace chemotherapy in combination treatment of relapsed, refractory CLL patients.

By Ned Pagliarulo • Sept. 18, 2017

Nabriva shares leap higher on antibiotic trial success

Positive results from Nabriva's LEAP 1 study augur well for the potential of the company's novel anti-infective in a common type of bacterial pneumonia. 

By Ned Pagliarulo • Sept. 18, 2017

EMA backs approval for J&J's Tremfya

A positive opinion from the EU drugs regulator sets up J&J to expand Tremfya's market to Europe. 

By Suzanne Elvidge • Sept. 18, 2017

FDA places two combo studies of Roche's Tecentriq on partial hold

The decision follows recruitment halts for a number of other trials involving PD-(L)1 inhibitors in certain blood cancers due to safety concerns.

By Suzanne Elvidge • Sept. 18, 2017

AstraZeneca's Bydureon falls short in heart study

Lack of a heart benefit means a comeback for Bydureon probably isn't in the cards.

By Lisa LaMotta • Sept. 14, 2017

Lilly's baricitinib fails to outshine Sanofi's Dupixent

A mid-stage study in atopic dermatitis hit its goal, but results appeared to fall short of the mark set by Sanofi and Regeneron's already approved treatment.

By Lisa LaMotta • Sept. 14, 2017

Pfizer, Astellas eye wider market for prostate cancer drug

Xtandi's broader commercial prospects were a key factor in Pfizer's decision to pick up the drug in a $14 billion acquisition of Medivation last fall.

By Ned Pagliarulo • Sept. 14, 2017

Lexicon, Sanofi drug could be first oral for type 1 diabetes

Positive results in three Phase 3 trials could set the SGTL1/SGLT2 inhibitor up to be the first oral treatment for the less common form of the chronic condition.

By Lisa LaMotta • Sept. 13, 2017